Source comparison
CJC-1295 vs Tesamorelin
Tesamorelin is the only GHRH analog with current FDA approval (granted in 2010 for HIV-associated lipodystrophy). It uses an N-terminal trans-3-hexenoic acid modification for DPP-4 resistance, giving it a half-life of approximately 26 to 38 minutes, comparable
This comparison does not assign a generated winner or score.
- Tesamorelin is the only GHRH analog with current FDA approval (granted in 2010 for HIV-associated lipodystrophy). It uses an N-terminal trans-3-hexenoic acid modification for DPP-4 resistance, giving it a half-life of approximately 26 to 38 minutes, comparable to CJC-1295 without DAC. Tesamorelin has Phase III randomized controlled trial data, making it the best-characterized GHRH analog from an evidence standpoint. Its primary clinical indication is visceral fat reduction, and it requires daily injection. CJC-1295 lacks equivalent clinical trial data but is more commonly used in combination stacking protocols.